JP2023123726A5 - - Google Patents

Download PDF

Info

Publication number
JP2023123726A5
JP2023123726A5 JP2023105929A JP2023105929A JP2023123726A5 JP 2023123726 A5 JP2023123726 A5 JP 2023123726A5 JP 2023105929 A JP2023105929 A JP 2023105929A JP 2023105929 A JP2023105929 A JP 2023105929A JP 2023123726 A5 JP2023123726 A5 JP 2023123726A5
Authority
JP
Japan
Prior art keywords
seq
hvr
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023105929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023123726A (ja
Filing date
Publication date
Priority claimed from PCT/JP2018/017495 external-priority patent/WO2018203567A1/en
Application filed filed Critical
Publication of JP2023123726A publication Critical patent/JP2023123726A/ja
Publication of JP2023123726A5 publication Critical patent/JP2023123726A5/ja
Pending legal-status Critical Current

Links

JP2023105929A 2017-05-02 2023-06-28 細胞傷害誘導治療剤 Pending JP2023123726A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017091955 2017-05-02
JP2017091955 2017-05-02
PCT/JP2018/017495 WO2018203567A1 (en) 2017-05-02 2018-05-02 Cytotoxicity-inducing therapeutic agent
JP2019559378A JP2020518584A (ja) 2017-05-02 2018-05-02 細胞傷害誘導治療剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019559378A Division JP2020518584A (ja) 2017-05-02 2018-05-02 細胞傷害誘導治療剤

Publications (2)

Publication Number Publication Date
JP2023123726A JP2023123726A (ja) 2023-09-05
JP2023123726A5 true JP2023123726A5 (Direct) 2025-08-05

Family

ID=64016153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019559378A Pending JP2020518584A (ja) 2017-05-02 2018-05-02 細胞傷害誘導治療剤
JP2023105929A Pending JP2023123726A (ja) 2017-05-02 2023-06-28 細胞傷害誘導治療剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019559378A Pending JP2020518584A (ja) 2017-05-02 2018-05-02 細胞傷害誘導治療剤

Country Status (4)

Country Link
US (2) US20200123256A1 (Direct)
EP (1) EP3619238A4 (Direct)
JP (2) JP2020518584A (Direct)
WO (1) WO2018203567A1 (Direct)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647707B1 (en) 2010-11-30 2018-09-12 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
RU2681885C2 (ru) 2011-10-31 2019-03-13 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула с регулируемой конъюгацией между тяжелой цепью и легкой цепью
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
AU2018207440B2 (en) 2017-01-11 2022-06-02 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (RSPO) surrogate molecules
CN110234662A (zh) 2017-01-26 2019-09-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
US12466884B2 (en) 2018-07-09 2025-11-11 Surrozen Operating, Inc. Tissue-specific WNT signal enhancing molecules and uses
US12454580B2 (en) 2020-04-10 2025-10-28 Regeneron Pharmaceuticals, Inc. FRB antibodies
CN112175080B (zh) * 2020-10-22 2021-05-25 优睿赛思(武汉)生物科技有限公司 抗人白介素-6高亲和力兔单克隆抗体及应用
TW202233656A (zh) 2020-11-16 2022-09-01 美商蘇羅森營運公司 肝特異性wnt訊號增強分子及其用途
WO2022169872A1 (en) * 2021-02-03 2022-08-11 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
JP2025508949A (ja) * 2022-02-28 2025-04-10 アデプト セラピューティクス インコーポレイテッド 抗プログラム細胞死リガンド1(pd-l1)抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201809385RA (en) * 2013-12-17 2018-11-29 Genentech Inc Anti-cd3 antibodies and methods of use
BR112016024525A2 (pt) * 2014-04-21 2017-10-10 Abbvie Stemcentrx Llc novos anticorpos anti-rnf43 e métodos de uso
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3288981A1 (en) * 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2023123726A5 (Direct)
JP2019502712A5 (Direct)
JP2022031635A5 (Direct)
JP2020180158A5 (Direct)
JP2018522541A5 (Direct)
JP2023134618A5 (Direct)
CN115702008A (zh) 抗体药物偶联物
JP2018108081A5 (Direct)
JP2017514461A5 (Direct)
JP2017534577A5 (Direct)
JP2023116744A5 (Direct)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2018527887A5 (Direct)
FI4141032T3 (fi) T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
HRP20240939T1 (hr) Anti-cd3 protutijela i metode uporabe
JP2020502233A5 (Direct)
JPWO2019204564A5 (Direct)
FI3452515T3 (fi) HER-2 sitoutuvia vasta-aineita
JPWO2018206790A5 (Direct)
JPWO2022044573A5 (Direct)
JP2023103352A5 (Direct)
JPWO2020033664A5 (Direct)
IL277899B2 (en) Methods and preparations for treating yellow fever
JPWO2019201959A5 (Direct)
JPWO2022256559A5 (Direct)